Classification of Implantable Devices Under MDR

Under EU MDR Annex VIII, most implantable devices are classified as Class IIb or Class III. Class III includes all implantable devices that are active, that interact with the central nervous or cardiac system, or that present high-risk characteristics. Class IIb includes most other implants (e.g., non-active orthopaedic implants, dental implants). Some previously Class IIa devices (e.g., sutures, staples, dental materials) have been reclassified to Class IIb or III under MDR, creating new compliance challenges for manufacturers who previously operated under lighter MDD requirements.

Clinical Evidence Requirements

The most significant compliance challenge for implantable device manufacturers is clinical evidence. MDR requires that all Class III and most Class IIb implantable devices have clinical evidence from clinical investigations or a robust analysis of clinical data from equivalent devices. 'Equivalence' under MDR is strictly defined: the device must be clinically, technically, and biologically equivalent to the predicate, and the manufacturer must have access to the predicate's technical documentation. Relying on literature data alone is increasingly scrutinised; clinical investigations may be required for novel implants without an established clinical evidence base.

Post-Market Clinical Follow-Up (PMCF)

All implantable devices require a Post-Market Clinical Follow-Up (PMCF) plan. PMCF must demonstrate the continued safety and performance of the device through active data collection in the post-market phase. This includes patient registries, systematic literature surveillance, Post-Market Surveillance studies, and where indicated, formal clinical studies. PMCF data feeds into the Clinical Evaluation Report (CER) and the benefit-risk analysis, which must be updated at least annually for Class III devices. PMCF plans that propose only literature surveillance without active patient follow-up will be challenged by Notified Bodies for high-risk implantable devices.

Implant Card and Patient Information Requirements

EU MDR Article 18 requires manufacturers of implantable devices to provide patients with an implant card containing key information about the device: device name, serial/batch number, implantation date, manufacturer name and address, and any specific instructions for post-implantation care or precautions. This information must be provided in the language(s) of the EU member state where the implantation takes place. For implants used in MRI environments, specific MRI safety information must be included. The implant card obligation is a new MDR requirement with no MDD equivalent — non-compliance is cited in audits.

UDI Requirements for Implantable Devices

Implantable devices have the most stringent UDI (Unique Device Identification) requirements under MDR. Class III implantable devices require UDI on the device itself (direct part marking) in addition to the packaging — a requirement that demands production process investment for laser or electrochemical marking on small implants. All UDI data must be uploaded to EUDAMED once fully operational. Serialisation (individual serial numbers for each unit) is required for Class III implantable devices, as opposed to lot-level identification for lower-risk devices.

Biocompatibility: ISO 10993 Under MDR

Implantable devices face the most rigorous biocompatibility requirements under ISO 10993. EU MDR General Safety and Performance Requirement 10.4 explicitly requires biological safety evaluation following ISO 10993-1. For implants, this typically requires: cytotoxicity, sensitisation, irritation, systemic toxicity, sub-chronic/chronic toxicity, genotoxicity, implantation, and hemocompatibility testing. The newly published ISO 10993-1:2025 introduces updated guidance on toxicological risk assessment and chemical characterisation — manufacturers should assess whether their existing biocompatibility data remains sufficient under the updated standard.

Scrutiny Procedure for Certain Class III Devices

EU MDR Article 54 introduces a new 'scrutiny procedure' for certain high-risk Class III implantable devices (including total joint replacement implants, spinal implants, cardiac implants, and breast implants). Under this procedure, the Notified Body must consult a pool of EU clinical experts before issuing a Certificate of Conformity for a new device. This adds an additional layer of review — and potentially significant additional time — to the CE certification process for these device categories.

Conclusion

Implantable device manufacturers face the most demanding and expensive MDR compliance pathway. Early investment in clinical evidence, PMCF infrastructure, and UDI systems is essential. Turkish manufacturers of orthopaedic, dental, cardiovascular, or other implantable devices who have not yet engaged a Notified Body for MDR conformity assessment should treat this as the highest regulatory priority.